Delmar Pharmaceuticals Inc. (DMPI) 6.58 $DMPI
DelMar Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell on July 14
PR Newswire - Wed Jul 13, 7:30AM CDT
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" and the "Company"
, a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the Company will ring the Nasdaq Opening Bell on Thursday, July 14 in honor of its recent listing on Nasdaq. Members of the DelMar Pharmaceuticals corporate team including Jeffrey Bacha, Chairman and CEO, will ring the opening bell in celebration of the listing.
DMPI: 6.58 (-0.32)
DelMar Pharmaceuticals Announces Approval for Listing on NASDAQ
PR Newswire - Mon Jul 11, 7:49AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", a company focused on developing and commercializing proven cancer therapies in new orphan drug indications, announced today that it has received approval from the Nasdaq Stock Market LLC ("NASDAQ" for the listing of its common stock on the NASDAQ Capital Market.
DMPI: 6.58 (-0.32)
DelMar Pharmaceuticals Presents Phase I/II GBM Clinical Trial Data and Outlines Future Clinical Development Plans at ASCO 2016 Annual Meeting
PR Newswire - Mon Jun 06, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPID) ("DelMar" and the "Company", a company focused on developing and commercializing proven cancer therapies in new orphan drug indications, presented new data from its recently completed Phase I/II clinical trial of VAL-083 (dianhydrogalactitol) at the American Society of Clinical Oncology's (ASCO) Annual Meeting on Saturday, June 4, 2016.
DMPI: 6.58 (-0.32)
DelMar Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting with FDA on VAL-083 for the Treatment of Refractory Glioblastoma Multiforme
PR Newswire - Wed May 25, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", a company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced the successful completion of an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA).
DMPI: 6.58 (-0.32)
DelMar Pharmaceuticals, Inc. - "Reverse Stock Splits & Uplisting"
ACCESSWIRE - Thu May 19, 9:32AM CDT
NEW YORK, NY / ACCESSWIRE / May 19, 2016 / DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, Jeffrey Bacha. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
DMPI: 6.58 (-0.32)
DelMar Pharmaceuticals Announces Reverse Stock Split in Preparation for Proposed Senior Exchange Uplisting
PR Newswire - Thu May 19, 9:16AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", today announced a 1-for-4 reverse stock split of its authorized, issued and outstanding common stock in preparation for its planned uplisting to a senior stock exchange. The Company anticipates the reverse stock split will become effective and its common stock to begin trading on a post-split basis at the open of trading on May 20, 2016.
DMPI: 6.58 (-0.32)
DelMar Pharmaceuticals, Inc. - "60 Minutes, Polio Virus for GBM, and the Promise of Chemo-Immunooncology"
ACCESSWIRE - Mon May 16, 9:22AM CDT
NEW YORK, NY / ACCESSWIRE / May 16, 2016 / DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, Jeffrey Bacha. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
DMPI: 6.58 (-0.32)
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2016 Financial Results and Corporate Update
PR Newswire - Fri May 13, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced its financial results for the quarter ending March 31, 2016, the third quarter of the 2016 fiscal year. The Company also highlighted recent corporate and clinical achievements and provided an overview of expected near-term milestones.
DMPI: 6.58 (-0.32)
DelMar Pharmaceuticals, Inc. Announces $5.6 Million Private Placement Of Preferred Shares
PR Newswire - Thu May 05, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced a closing of a private placement of Preferred Shares for gross proceeds of $5.6 million, and the restructuring of 2,095,238 warrants. These steps enable DelMar to substantially improve its balance sheet, remove a significant portion of the derivative liability from its balance sheet and help position the Company to qualify to list its common stock on a senior exchange.
DMPI: 6.58 (-0.32)
FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer
PR Newswire - Thu Apr 21, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of ovarian cancer. The investigational drug candidate previously received an orphan designation for glioma and medulloblastoma in the United States and glioma in Europe.
DMPI: 6.58 (-0.32)
DelMar Pharmaceuticals Announces New Data Supporting the Unique Anti-cancer Mechanism of VAL-083
PR Newswire - Tue Apr 19, 8:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that its collaborators from the University of British Columbia's Vancouver Prostate Center presented results of new research related to the anti-cancer mechanism of its lead anti-cancer product candidate, VAL-083 (dianhydrogalactitol).
DMPI: 6.58 (-0.32)
SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) Highlighting Partnership with MD Anderson
ACCESSWIRE - Thu Apr 14, 8:02AM CDT
NEW YORK, NY / ACCESSWIRE / April 14, 2016 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
DMPI: 6.58 (-0.32)
Four Biotech Stocks To Consider As The Sector Breaks Out
ACCESSWIRE - Thu Apr 07, 11:57AM CDT
NEW YORK, NY / ACCESSWIRE / April 7, 2016 / Has biotech finally bottomed? After an 8-month long bear market with biotech stocks losing over 40%, signs of a breakout are now becoming more and more obvious. All eyes are on the iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) as the 50 day moving average has been overtaken since the beginning of the month.
VRX: 22.30 (-0.83), CRBP: 2.77 (-0.08), DMPI: 6.58 (-0.32), IBB: 289.44 (+1.76), SPPI: 6.87 (+0.05)
Booming Orphan Drug Market Provides Investors with Massive Return Prospects
ACCESSWIRE - Wed Mar 30, 6:01AM CDT
WINDSOR, ON / ACCESSWIRE / March 30, 2016 / The Wealthy Biotech Trader (or "WBT", an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, would like to highlight the massive potential in a number of biotechs pursuing orphan drugs.
CPXX: 30.24 (unch), DMPI: 6.58 (-0.32), DNAI: 1.97 (-0.01)
DelMar Pharmaceuticals Announces Abstract Presentations for the American Association Cancer Research (AACR) Annual Meeting in April 2016
PR Newswire - Thu Mar 24, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it will present three abstracts at the American Association of Cancer Research (AACR) Annual Meeting based on pre-clinical research conducted with its lead anti-cancer product candidate, VAL-083 (dianhydrogalactitol), a "first-in-class" small-molecule chemotherapeutic agent.
DMPI: 6.58 (-0.32)
Orphan Drugs On a Roll, A Look Into the 2016 Orphan Space
ACCESSWIRE - Mon Mar 21, 8:15AM CDT
NEW YORK, NY / ACCESSWIRE / March 21, 2016 / The Food and Drug Administration approved 44 drugs in 2015. Of those 44, 17 were orphan drugs, defined as addressing less than 200,000 people in the United States. That's almost 40% of all drug approvals last year. In 2014, approvals were even more skewed in favor of orphans. Of the 41 drugs that gained FDA approval in 2014, 17 again were orphans. That's over 42%. In the last two years then, 40% of all new approved drugs have been orphans, definitely outsized representation given that orphan diseases are by definition rare.
BLCM: 15.88 (+0.13), AZN: 34.14 (-0.15), DMPI: 6.58 (-0.32), DNAI: 1.97 (-0.01)
DelMar Pharmaceuticals, Inc. - "Unlocking the Value of Independent Commercialization"
ACCESSWIRE - Wed Mar 16, 7:40AM CDT
NEW YORK, NY / ACCESSWIRE / March 16, 2016 / DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, Jeffrey Bacha. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
DMPI: 6.58 (-0.32)
FDA Grants Second Orphan Designation For VAL-083
PR Newswire - Tue Mar 15, 7:30AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of medulloblastoma. The investigational drug candidate previously received an orphan designation for glioblastoma in the United States and in Europe.
DMPI: 6.58 (-0.32)
UPDATE -- OTCQX and OTCQB Companies to Present at 2016 Roth Conference
PR Newswire - Mon Mar 14, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 3.76 (-0.10), DMPI: 6.58 (-0.32), CDXC: 4.00 (+0.04)
DelMar Pharmaceuticals, Inc. - "GBM After Rintegra(R)"
ACCESSWIRE - Fri Mar 11, 7:40AM CST
NEW YORK, NY / ACCESSWIRE / March 11, 2016 / Delmar Pharmaceuticals, Inc. (OTCQX: DMPI) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, Jeffrey Bacha. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
CLDX: 4.62 (-0.10), DMPI: 6.58 (-0.32)
DelMar Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell on July 14
PR Newswire - Wed Jul 13, 7:30AM CDT
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" and the "Company"
, a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the Company will ring the Nasdaq Opening Bell on Thursday, July 14 in honor of its recent listing on Nasdaq. Members of the DelMar Pharmaceuticals corporate team including Jeffrey Bacha, Chairman and CEO, will ring the opening bell in celebration of the listing. DMPI: 6.58 (-0.32)
DelMar Pharmaceuticals Announces Approval for Listing on NASDAQ
PR Newswire - Mon Jul 11, 7:49AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, a company focused on developing and commercializing proven cancer therapies in new orphan drug indications, announced today that it has received approval from the Nasdaq Stock Market LLC ("NASDAQ" for the listing of its common stock on the NASDAQ Capital Market. DMPI: 6.58 (-0.32)
DelMar Pharmaceuticals Presents Phase I/II GBM Clinical Trial Data and Outlines Future Clinical Development Plans at ASCO 2016 Annual Meeting
PR Newswire - Mon Jun 06, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPID) ("DelMar" and the "Company"
, a company focused on developing and commercializing proven cancer therapies in new orphan drug indications, presented new data from its recently completed Phase I/II clinical trial of VAL-083 (dianhydrogalactitol) at the American Society of Clinical Oncology's (ASCO) Annual Meeting on Saturday, June 4, 2016. DMPI: 6.58 (-0.32)
DelMar Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting with FDA on VAL-083 for the Treatment of Refractory Glioblastoma Multiforme
PR Newswire - Wed May 25, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, a company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced the successful completion of an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). DMPI: 6.58 (-0.32)
DelMar Pharmaceuticals, Inc. - "Reverse Stock Splits & Uplisting"
ACCESSWIRE - Thu May 19, 9:32AM CDT
NEW YORK, NY / ACCESSWIRE / May 19, 2016 / DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, Jeffrey Bacha. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
DMPI: 6.58 (-0.32)
DelMar Pharmaceuticals Announces Reverse Stock Split in Preparation for Proposed Senior Exchange Uplisting
PR Newswire - Thu May 19, 9:16AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, today announced a 1-for-4 reverse stock split of its authorized, issued and outstanding common stock in preparation for its planned uplisting to a senior stock exchange. The Company anticipates the reverse stock split will become effective and its common stock to begin trading on a post-split basis at the open of trading on May 20, 2016. DMPI: 6.58 (-0.32)
DelMar Pharmaceuticals, Inc. - "60 Minutes, Polio Virus for GBM, and the Promise of Chemo-Immunooncology"
ACCESSWIRE - Mon May 16, 9:22AM CDT
NEW YORK, NY / ACCESSWIRE / May 16, 2016 / DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, Jeffrey Bacha. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
DMPI: 6.58 (-0.32)
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2016 Financial Results and Corporate Update
PR Newswire - Fri May 13, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced its financial results for the quarter ending March 31, 2016, the third quarter of the 2016 fiscal year. The Company also highlighted recent corporate and clinical achievements and provided an overview of expected near-term milestones. DMPI: 6.58 (-0.32)
DelMar Pharmaceuticals, Inc. Announces $5.6 Million Private Placement Of Preferred Shares
PR Newswire - Thu May 05, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced a closing of a private placement of Preferred Shares for gross proceeds of $5.6 million, and the restructuring of 2,095,238 warrants. These steps enable DelMar to substantially improve its balance sheet, remove a significant portion of the derivative liability from its balance sheet and help position the Company to qualify to list its common stock on a senior exchange. DMPI: 6.58 (-0.32)
FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer
PR Newswire - Thu Apr 21, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of ovarian cancer. The investigational drug candidate previously received an orphan designation for glioma and medulloblastoma in the United States and glioma in Europe. DMPI: 6.58 (-0.32)
DelMar Pharmaceuticals Announces New Data Supporting the Unique Anti-cancer Mechanism of VAL-083
PR Newswire - Tue Apr 19, 8:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that its collaborators from the University of British Columbia's Vancouver Prostate Center presented results of new research related to the anti-cancer mechanism of its lead anti-cancer product candidate, VAL-083 (dianhydrogalactitol). DMPI: 6.58 (-0.32)
SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) Highlighting Partnership with MD Anderson
ACCESSWIRE - Thu Apr 14, 8:02AM CDT
NEW YORK, NY / ACCESSWIRE / April 14, 2016 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
DMPI: 6.58 (-0.32)
Four Biotech Stocks To Consider As The Sector Breaks Out
ACCESSWIRE - Thu Apr 07, 11:57AM CDT
NEW YORK, NY / ACCESSWIRE / April 7, 2016 / Has biotech finally bottomed? After an 8-month long bear market with biotech stocks losing over 40%, signs of a breakout are now becoming more and more obvious. All eyes are on the iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) as the 50 day moving average has been overtaken since the beginning of the month.
VRX: 22.30 (-0.83), CRBP: 2.77 (-0.08), DMPI: 6.58 (-0.32), IBB: 289.44 (+1.76), SPPI: 6.87 (+0.05)
Booming Orphan Drug Market Provides Investors with Massive Return Prospects
ACCESSWIRE - Wed Mar 30, 6:01AM CDT
WINDSOR, ON / ACCESSWIRE / March 30, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, would like to highlight the massive potential in a number of biotechs pursuing orphan drugs. CPXX: 30.24 (unch), DMPI: 6.58 (-0.32), DNAI: 1.97 (-0.01)
DelMar Pharmaceuticals Announces Abstract Presentations for the American Association Cancer Research (AACR) Annual Meeting in April 2016
PR Newswire - Thu Mar 24, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it will present three abstracts at the American Association of Cancer Research (AACR) Annual Meeting based on pre-clinical research conducted with its lead anti-cancer product candidate, VAL-083 (dianhydrogalactitol), a "first-in-class" small-molecule chemotherapeutic agent. DMPI: 6.58 (-0.32)
Orphan Drugs On a Roll, A Look Into the 2016 Orphan Space
ACCESSWIRE - Mon Mar 21, 8:15AM CDT
NEW YORK, NY / ACCESSWIRE / March 21, 2016 / The Food and Drug Administration approved 44 drugs in 2015. Of those 44, 17 were orphan drugs, defined as addressing less than 200,000 people in the United States. That's almost 40% of all drug approvals last year. In 2014, approvals were even more skewed in favor of orphans. Of the 41 drugs that gained FDA approval in 2014, 17 again were orphans. That's over 42%. In the last two years then, 40% of all new approved drugs have been orphans, definitely outsized representation given that orphan diseases are by definition rare.
BLCM: 15.88 (+0.13), AZN: 34.14 (-0.15), DMPI: 6.58 (-0.32), DNAI: 1.97 (-0.01)
DelMar Pharmaceuticals, Inc. - "Unlocking the Value of Independent Commercialization"
ACCESSWIRE - Wed Mar 16, 7:40AM CDT
NEW YORK, NY / ACCESSWIRE / March 16, 2016 / DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, Jeffrey Bacha. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
DMPI: 6.58 (-0.32)
FDA Grants Second Orphan Designation For VAL-083
PR Newswire - Tue Mar 15, 7:30AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of medulloblastoma. The investigational drug candidate previously received an orphan designation for glioblastoma in the United States and in Europe. DMPI: 6.58 (-0.32)
UPDATE -- OTCQX and OTCQB Companies to Present at 2016 Roth Conference
PR Newswire - Mon Mar 14, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 3.76 (-0.10), DMPI: 6.58 (-0.32), CDXC: 4.00 (+0.04)
DelMar Pharmaceuticals, Inc. - "GBM After Rintegra(R)"
ACCESSWIRE - Fri Mar 11, 7:40AM CST
NEW YORK, NY / ACCESSWIRE / March 11, 2016 / Delmar Pharmaceuticals, Inc. (OTCQX: DMPI) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, Jeffrey Bacha. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
CLDX: 4.62 (-0.10), DMPI: 6.58 (-0.32)
